07/05/2026
Important Update: Expanded Funding for Melanoma Treatment
Starting 1 May 2026, Pharmac is widening funded access to life-changing immunotherapy treatments (Nivolumab and Ipilimumab) for advanced melanoma. This update is a major milestone for New Zealanders, ensuring our standard of care reflects the best international practices.
What this means for eligible patients:
- Earlier intervention: Medicines can now be used before surgery to help shrink tumours.
- Reduced burden: For many, this combined approach can lead to fewer follow-up requirements post-surgery.
- Better outcomes: A more effective pathway for those navigating Stage 3B to Stage 4 melanoma.
If you have questions about how these changes affect your or a loved one’s treatment plan, please reach out. Our GPs are here to help and support you.
For more information visit: melanoma.org.nz/increased-funding-for-melanoma-medicines-confirmed-from-1-may-2026/